1.Elble, RJ. What is essential tremor? Curr Neurol Neurosci Rep 2013; 13:353. DOI 10.1007/s11910-013-0353-4.
2.Borucki, MJ, Matzke, DS, Pollard, RB. Tremor induced by trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 77–78.
3.Patterson, RG, Couchenour, RI. Trimethoprim-sulfamethoxazole-induced tremor in an immunocompetent patient. Pharmacotherapy 1999; 19: 1456–1458.
4.Conget, JI, Vendrell, J, Halperin, I, Esmatjes, E. Widespread tremor after injection of sodium calcitonin. Br Med J 1989; 298: 189.
5.Brimblecombe, RW, Pinder, RM. Tremors and Tremorogenic Agents. Bristol (UK): Scientechnica, 1972.
6.LeWitt, PA. Tremor induced or enhanced by pharmacological means. In: Findley, L, Koller, WC (eds), Handbook of Tremor Disorders, New York: Marcel Dekker., Chap 34, pp 473–481, 1995.
7.Morgan, JC, Sethi, KD. Drug-induced tremors. Lancet Neurology 2005; 4:866–876.
8.Micheli, F, Cerosimo, MG. Drug-induced parkinsonism. Handbook of Clinical Neurology. 2007; 84:399–416.
9.Shin, H-W, Chung, SJ. Drug-induced parkinsonism. J Clin Neurol 2012; 8: 15–21.
10.Boshes, RA, Oepen, G, Handren, M. Flapping tremor produced by high-potency neuroleptics. J Clin Psychopharmacol 1991: 11: 76–77.
11.Friedman, JH. “Rubral” tremor induced by a neuroleptic drug. Mov Disord 1992; 42: 407–410.
12.Thomas, AA, Friedman, JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 2010; 33:14–16.
13.Calne, DB, Webster, RA. Tremor induced by tetrabenazine. Br J Pharmacol 1969; 37: 468–475.
14.Stacy, M, Jankovic, J. Tardive tremor. Mov Disord 1992; 7: 71–76.
15.Shprecher, D. Sensory trick with metoclopramide-associated tardive tremor. Br Med J Case Rep 2012 pii:bcr1120115/156. Doi: 10.1136/bcr-11-2011-5156.
16.Alonso-Navarro, H, Orti-Pareja, M, Jiménez-Jiménez, FJ et al. [Orthostatic tremor induced by pharmaceuticals]. Rev Neurol [in Spanish] 2004; 39: 834–836.
17.Hyman, NM, Dennis, PD, Sinclair, KG. Tremor due to sodium valproate. Neurology 1979; 29; 1177–1180.
18.Karas, BJ, Wilder, BJ, Hammond, EJ, Bauman, AW. Valproate tremors. Neurology 1982; 32: 428–432.
19.Rinnerthaler, M, Luef, G, Mueller, J, et al. Computerized tremor analysis of valproate induced tremor: a comparative study of controlled-release versus conventional valproate. Epilepsia 2005; 46: 320–323.
20.Lancman, ME, Asconape, JJ, Walker, F. Acetazolamine appears effective in the management of valproate-induced tremor. Mov Disord 1994; 9:369.
21.Kakisaka, Y, Ito, S, Ohara, T et al. Asymmetric drug-induced tremor: Rare feature of a common event. Pediatric Neurology 2013; 48: 479–480.
22.Bech, P, Thomsen, J, Prytz, S et al. The profile and severity of lithium-induced side-effects in mentally healthy subjects. Neuropsychobiology 1979; 5: 160–166.
23.Vestergaard, P, Poulstrup, I, Shou, M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78: 434–441.
24.Tyrer, P, Lee, I, Trotter, C. Physiologic characteristics of tremor after chronic lithium therapy. Br J Psychiatr 1981; 139: 851–853.
25.Gelenberg, AJ, Jefferson, JW. Lithium tremor. J Clin Psychiatr 1995; 56: 283–287.
26.Donaldson, IM, Cunningham, J. Persisting neurological sequelae of lithium carbonate therapy. Arch Neurol 1983; 40: 747–751.
27.Kronfol, Z, Greden, JF, Zis, AP. Imipramine-induced tremor: effects of a beta-adrenergic blocking agent. J Clin Psychiatr 1983; 44:225–226.
28.Serrano-Duenas, M. Fluoxetine-induced tremor: clinical features in 21 patients. Parkinsonism Relat Disord 2002; 8: 325–327.
29.Koller, W, Cone, S, Herbster, G. Caffeine and tremor. Neurology 1987;37):169–172.
30.Seddon, P, Bara, A, Ducharme, FM, Lasserson, TJ. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev 2006; (1):CD002885.
31.Cazzola, M, Matera, MG. Tremor and β(2)-adrenergic agents: is it a real clinical problem? Pulm Pharmacol Ther 2012; 25:4–10.
32.Buss, DC, Marshall, RW, Milligan, N, et al. The effect of intravenous aminophylline on essential tremor. Br J Clin Pharmacol 1997; 43:119–121.
33.Palakurthy, PR, Iyer, V, Meckler, RJ. Unusual neurotoxicity associated with amiodarone therapy. Ann Intern Med 1987; 147: 881–884.
34.Hilleman, D, Miller, MA, Parker, R et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 1998; 18:138S–145S.
35.Charness, ME, Morady, F, Scheinman, MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984; 34: 669–671.
36.Coulter, DM, Edwards, IR, Savage, RI. Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 1990; 103: 98–100.
37.Werner, EG, Olanow, CW. Parkinsonism and amiodarone therapy. Ann Neurol 1989; 25:630–632.
38.Peyrieux, JC, Boissel, JP, Leizorovicz, A. Relationship between plasma mexiletine levels at steady-state. Presence of ventricular arrhythmias and side effects. Fundam Clin Pharmacol 1987; 1:45–47.
39.Manolis, AS, Deering, TF, Cameron, J, Estes, NA. Mexetiline: pharmacology and therapeutic use. Clin Cardiol 1990; 13:349–359.
40.Rubenstein, A, Cabili, S. Tremor induced by procainamide. Am J Cardiol 1986; 57:340–341.
41.Marti-Masso, JF, Pozo, JJ. Cinnizarine-induced parkinsonism: ten years later. Mov Disord 1998; 13: 453–456.
42.Micheli, F, Fernandez-Pardal, M, Gatto, M et al. Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 37:881–884.
43.Dietz, AJ. Amphetamine-like reactions to phenylpropylamine. JAMA 1981; 245:439–442.
44.Supiyaphun, P, Chochaipanichnon, I, Kerekhanjanarong, V, Saengpaniel, S. A comparative study of the side effects between pseudoephedrine in loratidine plus pseudoephedrine sulfate repetabs and loratidine + pseudoephedrine sulfate in treatment of allergic rhinitis in Thai patients. J Med Assoc Thai 2002; 85: 722–727.
45.Wade, JC, Meyers, JD. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983; 98: 921–925.
46.Rashiq, S, Briewa, L, Mooney, M, et al. Distinguishing acyclovir neurotoxicity from encephalomyelitis. J Intern Med 1993: 234: 507–511.
47.Nadel, AM. Vidarabine therapy for herpes simplex encephalitis. The development of an unusual tremor during treatment. Arch Neurol 1981; 38: 384–385.
48.Buedge, DR, Chow, AW, Sacks, SL. Neurotoxic effects during vidarabine therapy for herpes zoster. Can Med Assoc J 1985; 132: 392–395.
49.Kahan, DB, Flechner, SM, Lorber, MI et al. Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for one to five years. Transplantation 1987; 43:197–204.
50.Amery, WK, Heykants, J. Essential tremor and flunarizine. Cephalalgia 1988; 8:227.
51.Capella, D, Laporte, JR, Castel, JM et al. Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine. Brit Med J 1988; 297: 722–723.
52.Koller, W, Orebaugh, C, Lawson, L, Potempa, K. Pindolol-induced tremor. Clin Neuropharmacol 1987; 10:449–452.
53.Topaktas, S, Onur, R, Dalkara, T. Calcium channel blockers and essential tremor. Eur Neurol 1987; 27:114–119.